---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-258537"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:23:37.535579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M

## Summary
- Dosing begun in celiac disease trial; topline data expected Q2 2025.
- Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.
- Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).
- Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split.

## SEC filing metadata
- accession: 0001193125-24-258537
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/0001193125-24-258537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/d892744d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-258537
- JSON: https://secwatch.observer/filing/0001193125-24-258537.json
- Plain text: https://secwatch.observer/filing/0001193125-24-258537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.